22 Results for "

p38+kinase

" in MedChemExpress (MCE) Product Catalog:
Products (22)

22 Results for "p38+kinase" in MCE Product Catalog:

137
137 Publications Verification
Cat. No.: HY-10295
CAS No.: 152121-30-7
Pureté:  99.89%
Domaines de recherche:  

Neurological Disease Cancer

SB 202190 is a selective p38 MAP kinase inhibitor with IC50s of 50 nM and 100 nM for p38α and p38β2, respectively. SB 202190 binds to the ATP pocket of the active recombinant human p38 kinase with a Kd of 38 nM. SB 202190 has anti-cancer activity and rescued memory deficits . SB202190 induces autophagy .
137
137 Publications Verification
Cat. No.: HY-10295A
CAS No.: 350228-36-3
Pureté:  99.66%
Domaines de recherche:  

Neurological Disease Cancer

SB 202190 hydrochloride is a selective p38 MAP kinase inhibitor with IC50s of 50 nM and 100 nM for p38α and p38β2, respectively. SB 202190 hydrochloride binds to the ATP pocket of the active recombinant human p38 kinase with a Kd of 38 nM. SB 202190 hydrochloride has anti-cancer activity . SB202190 hydrochloride induces autophagy .
51
51 Cited Publications
Cat. No.: HY-10320
CAS No.: 285983-48-4
Pureté:  99.76%
Synonyms: BIRB 796
Target:  

p38 MAPK Raf Autophagy

Domaines de recherche:  

Inflammation/Immunology Cancer

Doramapimod (BIRB 796) is an orally active, highly potent p38 MAPK inhibitor, which has an IC50 for p38α=38 nM, for p38β=65 nM, for p38γ=200 nM, and for p38δ=520 nM. Doramapimod has picomolar affinity for p38 kinase (Kd=0.1 nM). Doramapimod also inhibits B-Raf with an IC50 of 83 nM .
Cat. No.: HY-149850
CAS No.: 2929285-29-8
Target:  

p38 MAPK

Domaines de recherche:  

Inflammation/Immunology

p38 Kinase inhibitor 5 (AA6) is a potent p38 kinase inhibitor with an IC50 of 403.57 nM. p38 Kinase inhibitor 5 has anti-inflammatory activity .
Cat. No.: HY-177320
CAS No.: 836682-64-5
Target:  

p38 MAPK

Domaines de recherche:  

Inflammation/Immunology

p38 Kinase-IN-9 (example 4) is a p38 kinase inhibitor with an IC50 of <1 μM. p38 Kinase-IN-9 can be used for the study of p38 kinase mediated diseases, including inflammatory diseases .
Cat. No.: HY-171295
CAS No.: 815595-14-3
Target:  

p38 MAPK

Domaines de recherche:  

Inflammation/Immunology

p38 Kinase inhibitor 7 (Comp:XXXIX) is the inhibitor for p38α with an IC50 of 5.25 nM. p38 Kinase inhibitor 7 inhibits TNFα production in cell THP-1 with an IC50 of 5.88 nM .
Cat. No.: HY-153348
CAS No.: 13142-47-7
Target:  

p38 MAPK

Domaines de recherche:  

Cancer

p38 Kinase inhibitor 4 (compound 135) is a potent p38 inhibitor .
Cat. No.: HY-U00324
CAS No.: 635725-16-5
Target:  

p38 MAPK Autophagy

Domaines de recherche:  

Cancer

p38 MAPK-IN-2 is an inhibitor of p38 kinase.
Cat. No.: HY-19399
CAS No.: 276690-58-5
Synonyms: (-)-BRX 005; (-)-BRX 235
Target:  

p38 MAPK HSP

Domaines de recherche:  

Cardiovascular Disease

Iroxanadine (BRX 005) is a vasculoprotector. Iroxanadine is a p38 kinase and HSP protein dual activator. Iroxanadine has the potential for atherosclerosis and vascular diseases research .
Cat. No.: HY-19399A
CAS No.: 203805-20-3
Synonyms: BRX 005; BRX 235
Target:  

p38 MAPK HSP

Domaines de recherche:  

Cardiovascular Disease

(±)-Iroxanadine (BRX 005; BRX 235), a vasculoprotector, is a p38 kinase and HSP protein activator. (±)-Iroxanadine has the potential for atherosclerosis and vascular diseases research .
Cat. No.: HY-19399D
CAS No.: 276690-59-6
Synonyms: (-)-BRX 005 hydrochloride; (-)-BRX 235 hydrochloride
Target:  

p38 MAPK HSP

Domaines de recherche:  

Cardiovascular Disease

Iroxanadine (BRX 005) hydrochloride is a vasculoprotector. Iroxanadine is a p38 kinase and HSP protein dual activator. Iroxanadine hydrochloride has the potential for atherosclerosis and vascular diseases research .
Cat. No.: HY-114897
CAS No.: 188352-45-6
Target:  

p38 MAPK

Domaines de recherche:  

Inflammation/Immunology

L-167307 is an effective pyrrole-based p38 kinase inhibitor that can reduce secondary paw swelling in rat adjuvant-induced arthritis models .
Cat. No.: HY-19399B
CAS No.: 276690-61-0
Synonyms: (-)-BRX 005 sulfate; (-)-BRX 235 sulfate
Target:  

p38 MAPK HSP

Domaines de recherche:  

Cardiovascular Disease

Iroxanadine (BRX 005) sulfate is a vasculoprotector. Iroxanadine is a p38 kinase and HSP protein dual activator. Iroxanadine sulfate has the potential for atherosclerosis and vascular diseases research .
Cat. No.: HY-19399C
CAS No.: 276690-62-1
Synonyms: (-)-BRX 005 hydrobromide; (-)-BRX 235 hydrobromide
Target:  

p38 MAPK HSP

Domaines de recherche:  

Cardiovascular Disease

Iroxanadine hydrobromide (BRX 005) is a vasculoprotector. Iroxanadine is a p38 kinase and HSP protein dual activator. Iroxanadine hydrobromide has the potential for atherosclerosis and vascular diseases research .
Cat. No.: HY-101268
CAS No.: 1808287-83-3
Target:  

Bcr-Abl Src p38 MAPK

Domaines de recherche:  

Cancer

CHMFL-ABL-053 (Compound 18a) is a potent, selective, and orally available BCR-ABL, SRC and p38 kinase inhibitor with IC50 values of 70, 90 and 62 nM against ABL1, SRC and p38, respectively .
Cat. No.: HY-125068
CAS No.: 218160-26-0
Domaines de recherche:  

Inflammation/Immunology

RPR203494 is a potent inhibitor against CYP isozymes. RPR203494 shows inhibition against p38 kinase with an IC50 value of 9 nM and an EC50 value of 60 nM. RPR203494 demonstrates an inhibition of hepatic Cytochrome P450. RPR203494 is promising for research of rheumatoid arthritis (RA) .
Cat. No.: HY-10295AR
CAS No.: 350228-36-3
SB 202190 (hydrochloride) (Standard) is the analytical standard of SB 202190 (hydrochloride). This product is intended for research and analytical applications. SB 202190 hydrochloride is a selective p38 MAP kinase inhibitor with IC50s of 50 nM and 100 nM for p38α and p38β2, respectively. SB 202190 hydrochloride binds to the ATP pocket of the active recombinant human p38 kinase with a Kd of 38 nM. SB 202190 hydrochloride has anti-cancer activity . SB202190 hydrochloride induces autophagy .
Cat. No.: HY-171296
CAS No.: 815595-25-6
Target:  

p38 MAPK JNK

Domaines de recherche:  

Inflammation/Immunology

p38 Kinase inhibitor 8 (Compound CCLXXVIII) is the orally active inhibitor for p38β and JNK2α2 with IC50s of 6.3 nM and 53.6 nM. p38 Kinase inhibitor 8 exhibits anti-inflammatory effect in rats collagen-induced arthritis models .
Cat. No.: HY-10295R
CAS No.: 152121-30-7
SB 202190 (Standard) is the analytical standard of SB 202190. This product is intended for research and analytical applications. SB 202190 is a selective p38 MAP kinase inhibitor with IC50s of 50 nM and 100 nM for p38α and p38β2, respectively. SB 202190 binds to the ATP pocket of the active recombinant human p38 kinase with a Kd of 38 nM. SB 202190 has anti-cancer activity and rescued memory deficits . SB202190 induces autophagy .
Cat. No.: HY-10320R
CAS No.: 285983-48-4
Synonyms: BIRB 796 (Standard)
Domaines de recherche:  

Inflammation/Immunology Cancer

Doramapimod (Standard) is the analytical standard of Doramapimod. This product is intended for research and analytical applications. Doramapimod (BIRB 796) is an orally active, highly potent p38 MAPK inhibitor, which has an IC50 for p38α=38 nM, for p38β=65 nM, for p38γ=200 nM, and for p38δ=520 nM. Doramapimod has picomolar affinity for p38 kinase (Kd=0.1 nM). Doramapimod also inhibits B-Raf with an IC50 of 83 nM .